Sökresultat - Portal för medicinska datamodeller (MDM-portal)

Follow-Up Ropinirole in Parkinson's Disease GSK 101468/196

- 2017-10-12 - 1 Formulär, 6 Item-grupper, 46 Dataelement, 1 Språk

Item-grupper: Patient Information, Orthostatic Blood Pressure, Compliance, Pregnancy Test, Completion of Dosing Period, Investigator Signature

Study ID: 101468/196 Clinical Study ID: 101468/196 Study Title: 101468/196: A Long-Term, Open-Label Continuation Study of Once Daily Administration of Ropinirole CR Tablets to Patients with Parkinson's Disease who Completed the Previous Ropinirole CR Studies 167 or 164 Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00650104 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication : Parkinson DiseaseA Long-Term, Open-Label Continuation Study of Once Daily Adminstration of Ropinirole CR Tablets to Patients with Parkinson's Disease Who Completed the Previous Ropinirole CR Studies - 167 & 164 Follow-Up

Follow-up - Ropinirole and the effect of food in early stage Parkinson’s disease subjects 101468/164

- 2017-10-10 - 1 Formulär, 18 Item-grupper, 72 Dataelement, 1 Språk

Item-grupper: Concomitant medication, Adverse event, Patient diary, 12-lead electrocardiogram report, orthostatic blood pressure / Pulse, Pregnancy test, Physical examination, Hematology Laboratory evaluation, Hematology Laboratory evaluation, Serum Laboratory evaluation, Serum laboratory evaluation, Urinalysis, Dip stick analysis, Microscopic analysis, Overall urinalysis assessment, Study Completion Part A, Study Completion Part B, Investigator signature

Follow-up - Ropinirole and the effect of food in early stage Parkinson’s disease subjects 101468/164 Study ID: 101468/164 Clinical Study ID: 101468/164 Study Title: An open-label, randomised, two part study to investigate the relative bioavailability of Ropinirole new and standard, marketed formulations and the effect of food on the pharmacokinetics of Ropinirole new formulation in early stage Parkinson’s disease subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL

Dose strength equivalence of ropinirole CR in healthy adults Follow-up Visit 101468/219 - Follow-up Visit Dose strength equivalence of ropinirole CR in healthy adults 101468/219

- 2017-08-17 - 1 Formulär, 10 Item-grupper, 63 Dataelement, 1 Språk

Item-grupper: Physical Examination, Pregnancy Test, ECG Monitoring, Vitals Signs, Clinical Chemistry and Haematology, Urinalysis, Adverse Event, Pregnancy Information, Study Conclusion, Investigators Statement

Study ID: 101468/219 Clinical Study ID: 101468/219 Study Title:An open label, randomised, five-way crossover single-dose pharmacokinetic study to assess dosage strength equivalence of ropinirole CR in healthy male and female volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Requip Study Indication : Parkinson Disease Documentation part: Follow-up Visit

Investigational Product Follow-up Ropinirole NCT00632736 - Investigational Product Follow-up

- 2017-07-30 - 1 Formulär, 1 Item-grupp, 5 Dataelement, 1 Språk

Item-grupp: Investigational Product

Study part: Investigational Product Follow-up.An Open-Label Extension phase 3 Study with REQUIP (ropinirole) CR for Subjects from Studies 101468/165, 101468/168 and 101468/169 Patient Level Data. Study ID:101468/248, Clinical Study ID: 101468/248.

Adverse Events Follow-up Ropinirole NCT00632736 - Adverse Events Follow-up

- 2017-07-30 - 1 Formulär, 1 Item-grupp, 1 Dataelement, 1 Språk

Item-grupp: Adverse Events

Study part: Adverse Events Follow-up. An Open-Label Extension phase 3 Study with REQUIP (ropinirole) CR for Subjects from Studies 101468/165, 101468/168 and 101468/169 Patient Level Data. Study ID:101468/248, Clinical Study ID: 101468/248.

Follow-Up Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole NCT00460148

- 2021-09-17 - 1 Formulär, 8 Item-grupper, 102 Dataelement, 1 Språk

Item-grupper: Subject Information, Physical Examination, Pregnancy Test (Complete for Female Subjects Only), Vital Signs, 12-Lead ECG, Local laboratory result data (Haematology), Local laboratory result data - (Clinical Chemistry), Urinalysis

Documentation Part: Follow-Up An Open Label, Repeat Dose, Dose Escalation Study Conducted in Parkinson's Disease Patients to Characterize the Pharmacokinetics and Effect of Food on Ropinirole Prolonged Release (PR/CR) 12mg Tablets. ClinicalTrials.gov Identifier: NCT00460148 https://clinicaltrials.gov/ct2/show/NCT00460148?term=NCT00460148&rank=1 Responsible Party: GlaxoSmithKline

Follow-Up 1 Parkinson Köln Core Data Set Ambulanz und Euroinf DBS

- 2016-06-11 - 1 Formulär, 8 Item-grupper, 115 Dataelement, 1 Språk

Item-grupper: Patient information, Treatment, Deep brain stimulation, UPDRS III 1FU MED ON/STIM OFF, UPDRS III 1FU MED OFF/STIM OFF, UPDRS III 1FU MED ON/STIM ON, UPDRS III 1FU MED OFF/STIM ON, Other scores

Parkinson Köln Core Data Set Ambulanz und Euroinn DBS Documentation part: Follow-Up 1 Source: Core Data Set Parkinson (Cologne, Prof. Dr. Lars Timmermann)

inital & follow-up report serious adverse events starting dose of ropinirole Parkinson's Disease 101468/166

- 2021-03-15 - 1 Formulär, 6 Item-grupper, 32 Dataelement, 1 Språk

Item-grupper: time of documentation, patient information, adverse event, study drug, patient information, principal investigator

Study ID: 101468/166 Clinical Study ID: SKF-101468/166 Study Title: A Phase II, randomised, double-blind, active-controlled, dose-escalation study to determine the maximum well-tolerated starting dose of a new formulation of ropinirole in Parkinson's Disease patients not receiving other dopaminergic therapies Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip Study Indication: Parkinson Disease

Follow-up visit week 38 compliance Ropinirole CR Ropinirole IR Monotherapy 101468/168

- 2017-10-17 - 1 Formulär, 3 Item-grupper, 10 Dataelement, 1 Språk

Item-grupper: administrative data, investigational product, compliance

Study ID: 101468/168 Clinical Study ID: 101468/168 Study Title: A Randomised, Double Blind, Three Period, Cross-Over Study of Ropinirole CR and Ropinirole IR Monotherapy Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara Study Indication: Parkinson Disease

Follow-up visit week 38 physical examination Ropinirole CR Ropinirole IR Monotherapy 101468/168

- 2017-10-17 - 1 Formulär, 2 Item-grupper, 7 Dataelement, 1 Språk

Item-grupper: administrative data, vital signs